ArticleJMIR dermatology2026
Local Deployment of Open-Weight Language Models in Dermatology: Viewpoint on Privacy, Equity, and Practical Implementation.
Article in JMIR dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlabelled: Generative AI, particularly large language models (LLMs), is reshaping clinical workflows in dermatology. However, cloud-based commercial models pose persistent challenges to Health Insurance Portability and Accountability Act (HIPAA) compliance, especially in dermatology, where protected health information (PHI) extends beyond text to clinical photographs, dermoscopic images, and total-body photography that may capture identifiable anatomical features and document conditions carrying social stigma. Locally hosted, open-weight LLMs that are run within the institution's own infrastructure offer dermatology practices a pathway to leverage AI capabilities while retaining full control of their data. This viewpoint synthesizes evidence on when locally hosted, open-weight LLMs should be preferred for dermatologic workflows, when cloud deployment may remain preferable, and how multimodal AI fits into a coherent local deployment strategy. We advance 4 arguments. First, model compression techniques (knowledge distillation, structured pruning, and low-bit quantization) together with mixture-of-experts architectures have lowered hardware thresholds enough that 7- to 33-billion-parameter models now run on consumer-grade workstations with modest neural processing units or graphics processing units. Second, dermatology is fundamentally a visual specialty, and a credible local deployment strategy must integrate LLMs with vision models, including convolutional neural networks, vision transformers, vision-language models, and dermatology-specific foundation models such as PanDerm and medical multimodal models such as MedGemma. Third, locally hosted, open-weight models confer specific advantages for dermatology, including complete institutional control of clinical images, freedom from vendor model deprecation that disrupts validated workflows, and the ability to audit and fine-tune models to address well-documented performance gaps in skin of color. Fourth, local deployment is not a panacea; cloud models remain preferable for some tasks, and local deployment introduces governance challenges (heterogeneity across practices, model drift, and quantization-induced accuracy loss) that require structured mitigation through validated reporting frameworks such as CONSORT-AI (Consolidated Standards of Reporting Trials), SPIRIT-AI (Standard Protocol Items: Recommendations for Interventional Trials), DECIDE-AI (Developmental and Exploratory Clinical Investigations of Decision support systems driven by AI), and TRIPOD+AI (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis), as well as retrieval-augmented generation and federated learning approaches. We situate these arguments within the international regulatory landscape, including the European Union's General Data Protection Regulation, the European Union AI Act, and Germany's
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.